Home/Federal Circuit/Valeant Pharmaceuticals v. Mylan Pharmaceuticals

Valeant Pharmaceuticals v. Mylan Pharmaceuticals

Procedural entryThis page is a short order in Valeant Pharmaceuticals v. Mylan Pharmaceuticals. Read the opinion of the Court — 978 F.3d 1374 →
Court of Appeals for the Federal Circuit·Decided November 6, 2020·No. 19-2402·Unpublished

Opinion

Case: 19-2402 Document: 74 Page: 1 Filed: 11/06/2020

United States Court of Appeals for the Federal Circuit

November 6, 2020

ERRATA

Appeal No. 2019-2402

VALEANT PHARMACEUTICALS NORTH AMERICA LLC, VALEANT PHARMACEUTICALS IRELAND LTD., DOW PHARMACEUTICAL SCIENCES, INC., KAKEN PHARMACEUTICAL CO., LTD., Plaintiffs-Appellants

v.

MYLAN PHARMACEUTICALS INC., MYLAN LABORATORIES LTD., MYLAN INC., Defendants-Appellees

Decided: November 5, 2020 Precedential Opinion

Please make the following change:

On page 6, line 10, change “Mylan” to —Valeant—.

Free access — add to your briefcase to read the full text and ask questions with AI

Valeant Pharmaceuticals v. Mylan Pharmaceuticals, (Fed. Cir. 2020).

Valeant Pharmaceuticals v. Mylan Pharmaceuticals (Valeant Pharmaceuticals v. Mylan Pharmaceuticals) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.